NBIX,ALKS Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: VTI IJH VB VBK VXF MDY IBB XBI FBT IWP

Index	-	P/E	26.59	EPS (ttm)	4.67	Insider Own	2.67%	Shs Outstand	100.10M	Perf Week	-12.10%
Market Cap	12.46B	Forward P/E	16.49	EPS next Y	7.53	Insider Trans	-3.64%	Shs Float	97.69M	Perf Month	-8.28%
Enterprise Value	11.45B	PEG	0.60	EPS next Q	1.09	Inst Own	98.96%	Short Float	3.42%	Perf Quarter	-15.48%
Income	478.60M	P/S	4.35	EPS this Y	27.16%	Inst Trans	0.21%	Short Ratio	3.09	Perf Half Y	-5.48%
Sales	2.86B	P/B	3.82	EPS next Y	26.73%	ROA	11.13%	Short Interest	3.34M	Perf YTD	-12.49%
Book/sh	32.50	P/C	8.41	EPS next 5Y	27.58%	ROE	16.38%	52W High	160.18 -22.51%	Perf Year	6.20%
Cash/sh	14.75	P/FCF	16.64	EPS past 3/5Y	44.05% 2.31%	ROIC	13.05%	52W Low	84.23 47.36%	Perf 3Y	19.90%
Dividend Est.	-	EV/EBITDA	17.17	Sales past 3/5Y	24.32% 22.29%	Gross Margin	98.18%	Volatility	4.38% 3.12%	Perf 5Y	8.78%
Dividend TTM	-	EV/Sales	4.00	EPS Y/Y TTM	41.73%	Oper. Margin	22.25%	ATR (14)	4.60	Perf 10Y	244.40%
Dividend Ex-Date	-	Quick Ratio	3.30	Sales Y/Y TTM	21.45%	Profit Margin	16.73%	RSI (14)	30.92	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	47.94%	SMA20	-8.35%	Beta	0.34	Target Price	177.29
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	28.33%	SMA50	-11.94%	Rel Volume	1.96	Prev Close	123.10
Employees	2000	LT Debt/Eq	0.13	Earnings	Feb 11 AMC	SMA200	-8.49%	Avg Volume	1.08M	Price	124.12
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.97% 1.90%	Trades		Volume	2,122,668	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130

Show Previous Ratings

Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Loading…
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
12:10PM	Loading…
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
04:05PM	Loading…
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR AVUV VTI IWM XBI VB FBT VBK SPSM VXF

Index	RUT	P/E	16.41	EPS (ttm)	2.02	Insider Own	2.33%	Shs Outstand	165.10M	Perf Week	-5.01%
Market Cap	5.48B	Forward P/E	18.95	EPS next Y	1.75	Insider Trans	-2.66%	Shs Float	161.27M	Perf Month	8.30%
Enterprise Value	4.44B	PEG	-	EPS next Q	0.41	Inst Own	107.16%	Short Float	11.78%	Perf Quarter	5.59%
Income	338.83M	P/S	3.60	EPS this Y	-39.79%	Inst Trans	2.48%	Short Ratio	9.50	Perf Half Y	17.34%
Sales	1.52B	P/B	3.16	EPS next Y	0.56%	ROA	15.08%	Short Interest	19.00M	Perf YTD	18.51%
Book/sh	10.50	P/C	4.93	EPS next 5Y	-14.29%	ROE	22.35%	52W High	36.45 -9.03%	Perf Year	-7.89%
Cash/sh	6.73	P/FCF	11.15	EPS past 3/5Y	- -	ROIC	18.84%	52W Low	25.17 31.77%	Perf 3Y	28.82%
Dividend Est.	-	EV/EBITDA	11.41	Sales past 3/5Y	9.89% 5.87%	Gross Margin	85.66%	Volatility	2.86% 3.47%	Perf 5Y	76.41%
Dividend TTM	-	EV/Sales	2.92	EPS Y/Y TTM	3.40%	Oper. Margin	23.57%	ATR (14)	1.15	Perf 10Y	9.93%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	1.08%	Profit Margin	22.27%	RSI (14)	51.69	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	3.67	EPS Q/Q	-11.21%	SMA20	-2.04%	Beta	0.52	Target Price	43.81
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	4.24%	SMA50	7.51%	Rel Volume	0.49	Prev Close	33.29
Employees	1800	LT Debt/Eq	0.04	Earnings	Feb 25 BMO	SMA200	11.13%	Avg Volume	2.00M	Price	33.16
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.55% 10.45%	Trades		Volume	989,058	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-25	Initiated	Truist	Buy	$50
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35

Show Previous Ratings

Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:20AM	Loading…
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
07:30AM	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market (Business Wire)
Feb-11-26 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 (Business Wire)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
10:38AM	Loading…
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:40AM	Loading…
09:40AM	Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Alkermes Stock? (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
Jan-27-26 02:07PM	BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down (Zacks)
12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
Jan-22-26 02:17PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)
03:09AM	Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" (Insider Monkey)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.61%
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-16-26 08:28PM	Lightning Round: Medline is 'unbelievable', it's a buy, says Jim Cramer (CNBC TV)
11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
Jan-14-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks) +5.04%
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
03:33AM	Best Value Stocks to Buy for Jan.14 (Zacks)
Jan-13-26 06:23PM	Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close (MarketBeat)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
Jan-06-26 07:00AM	Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 (Business Wire)
Dec-30-25 04:00PM	Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-25 06:50AM	Why Analysts are Rating Alkermes (ALKS) a Buy (Insider Monkey)
Dec-08-25 09:40AM	Are Investors Undervaluing Alkermes (ALKS) Right Now? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-25-25 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
Nov-19-25 04:22PM	Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck (Investor's Business Daily)
01:44PM	Alkermes prevails over Lundbeck in Avadel bidding war (Pharmaceutical Technology)
10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
09:12AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
06:00AM	Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc (PR Newswire)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
12:25AM	TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment (Insider Monkey)
Nov-18-25 01:23PM	RHHBY Reports Positive Phase III Data on Breast Cancer Drug (Zacks)
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks)
Nov-14-25 12:39PM	Health Care Roundup: Market Talk (The Wall Street Journal) -6.35%
11:38AM	To Wall Street, a new bidding war puts Alkermes in a tough spot (BioPharma Dive)
09:40AM	H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal (The Wall Street Journal)
09:19AM	Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid (Investor's Business Daily)
08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
07:45AM	Alkermes Response to Avadel Announcement (PR Newswire)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-12-25 12:16PM	Narcolepsy race heats up with Alkermes OX2R NT2 data but investors spooked (Clinical Trials Arena) -7.11%
09:35AM	DraftKings downgraded, Instacart upgraded: Wall Streets top analyst calls (TipRanks)
07:30AM	Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 (PR Newswire)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
11:40AM	ALKS or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	DraftKings downgraded, Instacart upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks)
09:55AM	Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Option Exercise	19.34	5,000	96,700	66,740	Feb 02 08:52 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Sale	33.93	9,000	305,384	57,740	Feb 02 08:52 PM
Cooke Shane	Director	Feb 02 '26	Option Exercise	31.64	61,200	1,936,368	164,944	Feb 02 08:48 PM
Cooke Shane	Director	Feb 02 '26	Sale	34.57	61,200	2,115,673	103,744	Feb 02 08:48 PM
Cooke Shane	Officer	Feb 02 '26	Proposed Sale	34.57	61,200	2,115,674		Feb 02 04:05 PM
Hopkinson Craig C.	Officer	Feb 02 '26	Proposed Sale	33.93	9,000	305,384		Feb 02 04:02 PM
Hopkinson Craig C.	Officer	Jan 08 '26	Proposed Sale	30.00	5,000	150,005		Jan 08 07:38 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Option Exercise	19.34	5,000	96,700	66,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Sale	30.00	5,000	150,005	61,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 02 '26	Sale	28.00	4,000	112,000	61,740	Jan 02 04:39 PM
Hopkinson Craig C.	Officer	Jan 02 '26	Proposed Sale	28.00	4,000	112,000		Jan 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM

NBIX

Neurocrine Biosciences, Inc

ALKS

Alkermes plc

Upgrade your FINVIZ experience